As pancreatic cancer overexpresses EGFR, erlotinib combined with gemcitabine was also approved for first‐line treatment for pancreatic cancer because OS was significantly longer with erlotinib plus gemcitabine than with gemcitabine (median OS: 6.24 vs. 5.91 months; HR, 0.82; 95%CI: 0.69, 0.99; p = 0.038).135. This evidence concerns the gene EGFR and familial pancreatic carcinoma.